NEUROPACE INC (NPCE)
Health Care · Implantable neuromodulation devices for epilepsy and neurological disorders · NASDAQ
NeuroPace makes the RNS System, the only FDA-approved brain-responsive neuromodulation device that monitors and treats drug-resistant epilepsy by delivering personalized electrical stimulation directly at seizure sources.
What NEUROPACE INC does
NeuroPace is a medical device company that develops and commercializes the RNS System, a brain-responsive neuromodulation platform for treating drug-resistant epilepsy. The device continuously monitors brain electrical activity, recognizes patient-specific abnormal patterns, and delivers real-time imperceptible electrical pulses to prevent seizures at the source—typically requiring only about three minutes of stimulation per day. Beyond epilepsy, the company is pursuing indication expansions to include drug-resistant idiopathic generalized epilepsy and pediatric patients aged 12–17, and is investigating potential applications in depression, memory disorders, and PTSD. As of December 2025, over 8,000 patients have received the RNS System, and the company is expanding its commercial reach beyond Level 4 comprehensive epilepsy centers to reach approximately 1,800 additional epileptologists and functional neurosurgeons.
Themes: Epilepsy / drug-resistant seizures, Neuromodulation / brain stimulation, Brain-computer interfaces / neural monitoring, Neurosurgery / implantable devices, Mental health treatment (depression, PTSD), Real-world clinical evidence generation
Fundamentals
- Price$14.03 as of 2026-08-21 close
- Market cap$482M as of 2026-08-21
- 1-year return+62.8% 2025-08-21 close $8.62 → 2026-08-21 close $14.03
- P/En/a negative earnings
- Net margin-21.7% as of 2026-08-24
- Gross margin+78.3% as of 2026-08-24
- ROE-120.7% as of 2026-08-24
- Debt / equity4.08 as of 2026-08-24
- Revenue growth (YoY)+18.1% as of 2026-08-24
- Revenue CAGR (3y)+30.0% SEC XBRL
- Beta1.88 as of 2026-08-24
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How NPCE compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How NEUROPACE INC looks technically
NEUROPACE INC (NPCE) is trading 8.7% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 1 trading day ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive). It made a new 20-day low about 16 trading days ago. It is 28.4% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 8.7% below its 200-day average, the long-term trend line — a long-term downtrend | -8.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $15.35 | $15.35 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $15.36 | $15.36 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 15.375. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 1 trading day ago — a "death cross", a bearish long-term signal | 1 session |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 17.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30) | 43.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($13.32 to $15.38) — its "stochastic" reading is 34 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 34.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $19.60 | $19.60 |
|---|---|---|
| From the 52-week high | it is 28.4% below its 52-week high (its highest price of the past year) | -28.4% |
| Above the 52-week low | it is 71.7% above its 52-week low (its lowest price of the past year) | +71.7% |
| Below the 52-week high | it is 28.4% below its highest point of the past year | 28.4% |
| Since a 20-day breakout | it made a new 20-day low about 16 trading days ago | 16 sessions |
| Since a 55-day breakout | it made a new 55-day low about 16 trading days ago | 16 sessions |
| All-time high | its highest closing price on record is $27.38 (set on 2021-04-27) | $27.38 |
| Given back of the 52-week move | over the past year its closes ranged ($8.62 to $19.29), and it has given back around half of its rise from last year’s low — 49% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $12.35 to $12.70. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 49.3% |
| From the all-time high | it is 48.8% below its all-time high | -48.8% |
| Nearest price level | it is sitting right on a support level at $13.96 — a price it turned at twice since 2025-06-05, most recently on 2026-02-12. Since 2024-08-21 it has 10 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.5% |
| All-time low | its lowest closing price on record is $1.22 (set on 2022-12-28) | $1.22 |
| Above the all-time low | it is 1050.0% above its all-time low | +1,050% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 48th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7867 between its high and its low — about 5.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7867 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $13.06 and $15.55 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $13.06 – $14.31 – $15.55 |
| Typical daily range (% of price) | its price moves about 5.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.6% |
| Stretch from the 200-day average | it is trading 1.7 daily ranges below its 200-day average price (8.7% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.7 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.56× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.9% |
|---|---|---|
| Gap filled | a 5.9% gap down opened on 2026-08-12 has been "filled" 7 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 7 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 11.6 percentage points (the stock lost 9.2% while the market gained 2.3%) | -11.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 16.9 percentage points (the stock lost 13.8% while the market gained 3.1%) | -16.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 13.2 percentage points (the stock lost 2.2% while the market gained 11.1%) | -13.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 42.3 percentage points (the stock gained 62.8% while the market gained 20.5%) | +42.3% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 16% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.9% of the share price, which is taken to mean a barrier that gives way easily. | -15.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 9% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $15.42 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | -9.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 9% below the average price paid since it last reported on 2026-05-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $15.40 — a volume-weighted average of daily closes over 70 sessions, not a true tick-by-tick VWAP. | -8.9% |
Price levels it has turned at before
NPCE last closed at $14.03 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $13.96 | Support | 0.5% below the last close | turned there twice · 2025-06-05 to 2026-02-12 |
| $13.68 | Support | 2.5% below the last close | turned there four times · 2025-01-10 to 2026-05-13 |
| $14.80 | Resistance | 5.5% above the last close | turned there twice · 2026-01-30 to 2026-03-17 |
| $15.07 | Resistance | 7.4% above the last close | turned there twice · 2025-01-24 to 2026-01-02 |
| $12.67 | Support | 9.7% below the last close | turned there twice · 2026-03-20 to 2026-07-31 |
| $15.55 | Resistance | 10.8% above the last close | turned there five times · 2025-12-17 to 2026-08-11 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $15.38.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $6.36 and $9.80 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $15.38.
This reading has stood for 3 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · trendless / choppy (low ADX) · lagging the market · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.11 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$20.22 range $18.00 – $22.00; median $20.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NPCE
- Consensus EPS estimate-$0.1906 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Regulatory and clinical execution risk: NAUTILUS study for generalized epilepsy did not achieve its primary effectiveness endpoint, and future label expansion approvals (pediatric, generalized epilepsy) depend on successful clinical data and FDA clearance.","Market adoption and reimbursement: Although the company expanded qualification criteria in 2023, RNS System adoption depends on clinician training, insurance reimbursement decisions, and clinician comfort with neurosurgical implantation for patients with drug-resistant epilepsy.","Commercial execution and competition: The company is unprofitable with significant accumulated deficit ($559.1 million as of March 31, 2026) and must execute on targeted expansion to ~1,800 additional epileptologists and functional neurosurgeons while managing R&D costs for indication expansions and potential new neurological indications."]
What changed in the latest 10-Q
AI-assisted comparison of NPCE's 10-Q filed 2026-05-12 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing specifies 'drug-resistant idiopathic generalized epilepsy' instead of 'drug-resistant generalized epilepsy' (filed 2026-05-12)
- Newer filing adds: 'These data points from the Post-approval Study were presented at the American Academy of Neurology Annual Meeting in April 2025' (filed 2026-05-12)
- Newer filing adds details on NAUTILUS PMA-S filing in December 2025 with 77% median GTC seizure reduction at 18 months (filed 2026-05-12)
- Newer filing adds: 'we anticipate potential NAUTILUS PMA-S approval in mid-2026' (filed 2026-05-12)
- Newer filing adds: 'In 2025, in an effort to further support the pediatric focal epilepsy label expansion efforts that we began with the RESPONSE study, we began a collaboration' (filed 2026-05-12)
- Newer filing specifies NEST collaboration details as continuing into 2026 (filed 2026-05-12)
- Newer filing updates accumulated deficit to $559.1 million as of March 31, 2026 (filed 2026-05-12)
- Newer filing updates cash, cash equivalents and short-term investments to $54.0 million as of March 31, 2026 (filed 2026-05-12)
- Newer filing updates outstanding debt to $59.0 million as of March 31, 2026 (filed 2026-05-12)
- Removed:
- Older filing states 'There are no changes in the Company's plan to file the expanded label submission to the FDA prior to the end of 2025' (filed 2025-11-04)
- Older filing specifies 'We continue to actively engage with the FDA to finalize a pathway to submitting an application seeking the expanded indication' (filed 2025-11-04)
- Older filing has less detailed NAUTILUS data description (filed 2025-11-04)
- Older filing references accumulated deficit of $549.7 million as of September 30, 2025 (filed 2025-11-04)
- Older filing references cash, cash equivalents and short-term investments of $60.0 million as of September 30, 2025 (filed 2025-11-04)
- Older filing references outstanding debt of $58.7 million as of September 30, 2025 (filed 2025-11-04)
- Older filing states 'our existing cash, cash equivalents and short-term investments will allow us to continue our operations for at least the next 12 months' (filed 2025-11-04)
- Reworded:
- Older filing: 'drug-resistant generalized epilepsy' changed to 'drug-resistant idiopathic generalized epilepsy' in newer filing (filed 2026-05-12)
- Older filing: 'were presented at' changed to 'These data points from the Post-approval Study were presented at' (filed 2026-05-12)
- Older filing: 'pre-specified secondary endpoints' changed to 'pre-specified secondary endpoints did show meaningful and clinically significant seizure reduction' with added detail on GTC seizure reduction (filed 2026-05-12)
- Older filing: RESPONSE study collaboration reference restructured to emphasize 2025 initiation and 2026 continuation (filed 2026-05-12)
- Older filing statement about FDA engagement and filing pathway removed and replaced with specific December 2025 PMA-S filing announcement and mid-2026 approval anticipation (filed 2026-05-12)
- Notes:
- The newer filing appears truncated at the end ('Based on our current planned operations, we believe our existing cash, cash equivalents a'), preventing full comparison of the liquidity section
- Date references changed from September 30, 2025 to March 31, 2026 reflect normal quarterly progression rather than substantive narrative changes
Risk Factors
- Added:
- Added new risk factor bullet point: 'If we fail to comply with U.S. federal and state laws and regulations, including fraud and abuse and other healthcare laws and regulations, such as those relating to kickbacks and false claims for reimbursement, we could face substantial penalties and our business, financial condition and results of operations could be harmed;' (filed 2026-05-12)
- Added new risk factor bullet point: 'Recent changes in staffing levels at the FDA could create delays in its response to and review of our submissions for indication expansion, harming our growth potential and long range financial plans;' (filed 2026-05-12)
- Reworded:
- Changed 'drive adoption' to 'increase adoption' in second bullet point (filed 2026-05-12)
- Changed 'drug-resistant generalized epilepsy' to 'drug-resistant idiopathic generalized epilepsy' in ninth bullet point (filed 2026-05-12)
- Removed a risk factor about FDA staffing changes from the summary list and re-ordered subsequent items in the older filing (filed 2025-11-04 had it in a different position)
- Notes:
- The newer filing appears truncated mid-sentence at the end of the provided text, limiting full comparison of detailed risk descriptions
- Page numbering differs between filings (page 31-32 in newer vs. 37-38 in older), but this reflects document layout rather than content changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for NPCE — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding NPCE as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 3,659,003
- Reported value $48,115,891
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
NPCE had 822,126 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
NPCE had 2.40% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.94 days to cover at the same settlement.
- Reported short interest (shares) 822,126
- Short interest (% of shares outstanding) 2.40%
- Prior settlement (shares) 874,337
- Reported change -5.97%
- Days to cover (reported) 3.94
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NPCE vs…
Frequently asked questions
What does NEUROPACE INC (NPCE) do?
NeuroPace is a medical device company that develops and commercializes the RNS System, a brain-responsive neuromodulation platform for treating drug-resistant epilepsy. The device continuously monitors brain electrical activity, recognizes patient-specific abnormal patterns, and delivers real-time imperceptible electrical pulses to prevent seizures at the source—typically requiring only about three minutes of stimulation per day.
What sector is NEUROPACE INC (NPCE) in?
NEUROPACE INC (NPCE) is classified in the Health Care sector. Its industry is Implantable neuromodulation devices for epilepsy and neurological disorders. It trades on NASDAQ.
Who are NEUROPACE INC's (NPCE) competitors?
Notable peers of NEUROPACE INC (NPCE) include Medtronic, LivaNova, Boston Scientific and Abbott Laboratories. This peer set is informational only — not financial advice.
Is NEUROPACE INC (NPCE) overbought or oversold right now?
NEUROPACE INC (NPCE) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 43, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NPCE come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.